Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study

Cancer Causes and Control

Volumn 26, Issue 2, 2015, Pages 205-218

  Gilbert, Rebecca ^a   Bonilla, Carolina ^a   Metcalfe, Chris ^a   Lewis, Sarah ^a   Evans, David M ^a   Fraser, William D ^b   Kemp, John P ^a   Donovan, Jenny L ^a   Hamdy, Freddie C ^c   Neal, David E ^d   Lane, J Athene ^a   Smith, George Davey ^a   Lathrop, Mark ^e,f   Martin, Richard M ^a,g  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^f MCGILL UNIVERSITY   (Canada)

^g National Institute for Health Research ^*  (United Kingdom)

Author keywords

1,25 dihydroxyvitamin D; 25 hydroxyvitamin D; Prostate cancer; Vitamin D; Vitamin D pathway genes

Indexed keywords

25 HYDROXYVITAMIN D; BINDING PROTEIN; CALCITRIOL; PROSTATE SPECIFIC ANTIGEN; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; 25-HYDROXYVITAMIN D; CALCIDIOL 1 MONOOXYGENASE; COLECALCIFEROL 24 HYDROXYLASE; CYP24A1 PROTEIN, HUMAN; CYP27B1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SUN EXPOSURE; VITAMIN D METABOLISM; ALLELE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MIDDLE AGED; ODDS RATIO; PROSTATE TUMOR; RISK; RISK ASSESSMENT;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; AGED; ALLELES; BIOMARKERS, TUMOR; CALCITRIOL; CASE-CONTROL STUDIES; GENE-ENVIRONMENT INTERACTION; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; RISK ASSESSMENT; RISK FACTORS; VITAMIN D; VITAMIN D-BINDING PROTEIN; VITAMIN D3 24-HYDROXYLASE;

EID: 84925511641     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0500-5     Document Type: Article

References (51)

1. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95
2. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P (2004) The role of Vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 92:317–325
3. Willis MS, Wians FH (2003) The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin Chim Acta 330:57–83
4. Lokeshwar BL, Schwartz GG, Selzer MG et al (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089. Cancer Epidemiol Biomark Prev 8:241–248
5. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med 229:277–284
6. Schwartz GG (2005) Vitamin D and the epidemiology of prostate cancer. Semin Dial 18:276–289
7. Polek TC, Weigel NL (2002) Vitamin D and prostate cancer. J Androl 23:9–17
8. Gilbert R, Metcalfe C, Oliver SE et al (2009) Life course sun exposure and risk of prostate cancer: population-based nested case–control study and meta-analysis. Int J Cancer 125:1414–1423
9. World Cancer Research Fund/American Institute for Cancer R (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington
10. Gilbert R, Martin RM, Beynon R et al (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–340
11. Gilbert R, Metcalfe C, Fraser WD et al (2012) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 131:1187–1196
12. Gilbert R, Metcalfe C, Fraser WD et al (2012) Associations of circulating retinol, vitamin E and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage and grade. Cancer Causes Control 23:1865–1873
13. Davey Smith G (2011) Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr 6:27–43
14. Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1–22
15. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 101:7711–7715
16. Sakaki T, Kagawa N, Yamamoto K, Inouye K (2005) Metabolism of vitamin D-3 by cytochromes P450. Front Biosci 10:119–134
17. Speeckaert M, Huang GM, Delanghe JR, Taes YEC (2006) Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 372:33–42
18. Chen L, Davey Smith G, Evans DM et al (2009) Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomark Prev 18:2874–2881
19. Ahn J, Yu K, Stolzenberg-Solomon R et al (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19:2739–2745
20. Wang TJ, Zhang F, Richards JB et al (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376:180–188
21. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46:3095–3101
22. Ma J, Stampfer MJ, Gann PH et al (1998) Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prev 7:385–390
23. Ahn J, Albanes D, Berndt SI et al (2009) Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30:769–776
24. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E (2007) Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67:911–923
25. Ohori M, Wheeler TM, Scardino PT (1994) The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clin Correl Cancer 74:104–114
26. Lewis SJ, Murad A, Chen L et al (2010) Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One 5:e13485
27. Bonilla C, Gilbert R, Kemp JP et al (2013) Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin D and prostate cancer risk. Cancer Epidemiol Biomark Prev 22:597–606
28. Fraser WD, Durham BH, Berry JL, Mawer EB (1997) Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann Clin Biochem 34:632–637
29. Berry D, Vimaleswaran K, Whittaker J, Hingorani A, Hyppönen E (2012) Evaluation of genetic markers as instruments for Mendelian randomization studies on vitamin D. PLoS One 7:e37465
30. Palmer TM, Lawlor DA, Harbord RM et al (2011) Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 21:223–242
31. Rowlands MA, Holly JM, Gunnell D et al (2010) The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (prostate testing for cancer and treatment) study. Cancer Causes Control 21:1829–1842
32. Janssen KJM, Donders AR, Harrell FE Jr et al (2010) Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 63:721–727
33. Royston P (2009) Multiple imputation of missing values: further update of ice, with an emphasis on categorical variables. Stata J 9:466–477
34. Thompson IM, Ankerst DP, Chi C et al (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA: J Am Med Assoc 294:66–70
35. Hernán MA, Hernández-Díaz S, Robins JM (2004) A structural approach to selection bias. Epidemiology 15:615–625. doi:10.1097/01.ede.0000135174.63482.43
36. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909
37. Shui IM, Mucci LA, Kraft P et al (2012) Vitamin D-related genetic Variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case–control study. J Natl Cancer Inst 104:690–699
38. Mondul AM, Shui IM, Yu K et al (2013) Genetic variation in the vitamin D pathway in relation to risk of prostate cancer—results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomark Prev 22:688–696
39. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM (2003) Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomark Prev 12:23–27
40. Guo Z, Wen J, Kan Q et al (2013) Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects. Tumor Biol 34:3189–3200
41. Holt SK, Kwon EM, Koopmeiners JS et al (2010) Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 70:1448–1460
42. Gilbert R, Metcalfe C, Fraser WD et al (2013) Associations of circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D and vitamin D-pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Eur J Cancer Prev 22:121–125
43. Peehl DM, Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10:131–140
44. Barreto AM, Schwartz GG, Woodruff R, Cramer SD (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-Dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomark Prev 9:265–270
45. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med 229:277–284
46. Tuohimaa P, Golovko O, Kalueff A et al (2005) Calcidiol and prostate cancer. J Steroid Biochem Mol Biol 93:183–190
47. Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D (2013) Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 132:2940–2947
48. Gilbert R, Martin RM, Donovan J et al. (2014) Misclassification of outcome in case–control studies: methods for sensitivity analysis. Stat Methods Med Res
49. Epstein M, Andrén O, Kasperzyk J et al (2012) Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control 23:1359–1366
50. Chun RF, Peercy BE, Adams JS, Hewison M (2012) Vitamin D binding protein and monocyte response to 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: analysis by mathematical modeling. PLoS One 7(1):e30773
51. Cancer Research UK. (2014) CancerStats report prostate cancer—UK, Cancer Research UK. http://info.cancerresearchuk.org/cancerstats/types/prostate